HPMCAS is one of the lead polymers in ASD development. It is hydrophobic enough to stabilize supersaturation and soluble enough above its pH threshold to release the drug. When used properly, it provides the classic “spring and stay” profile: a rapid initial release followed by a sustained high drug concentration.
Yet ASD precipitation behavior remains unpredictable. Every formulator has seen the dissolution curve that should plateau but instead collapses, or the beautiful supersaturation for compound A that disappears for compound B.
The natural reflex in these situations, switching to more water-soluble polymers, such as PVPVA64 or HPC, often makes things worse. Those polymers frequently fail to prevent precipitation where HPMCAS, the less obviously soluble option, succeeds.
This is the HPMCAS Paradox. But it has a second layer: even when HPMCAS is clearly the right polymer, the grade decision remains unpredictable. One API holds supersaturation only on HPMCAS-H (slower release, strongest stabilizer), while a chemically similar API works perfectly well on HPMCAS-L (fast releaser, weakest stabilizer). Until now, determining which API and HPMCAS grade combination ensures “spring and stay” has been purely a matter of trial and error.
In two joint publications with Shin-Etsu Life Sciences, we aimed to address this gap and understand what exactly makes HPMCAS such a great polymer and why.
Publication 1: HPMCAS is a dual-function polymer
In Nakhla et al., Int. J. Pharm. X, 2025, we demonstrated that in high drug-load nifedipine (NIF) ASD tablets prepared by hot-melt extrusion, HPMCAS has a dual function. It acts as a:
– Precipitation inhibitor maintaining supersaturation long enough to be biopharmaceutically meaningful and preventing drug re-crystallization.
– Dry binder enabling compressibility, leading to superior tablet tensile strength at drug loads up to 65%, where most polymers fail.
This powerful combination explains why HPMCAS is so valuable for high drug-load ASDs and can significantly improve bioavailability.
The experiment clearly showed that HPMCAS held supersaturation, whereas the more soluble-looking alternatives could not. Pre-dissolved water-soluble polymers (PVPVA64 and HPC) did not prevent NIF precipitation. HPMCAS, the less obviously soluble option, did.
So, publication 1 demonstrated what HPMCAS is doing. But two questions remained open: Why does HPMCAS hold supersaturation when more soluble polymers cannot? And how can a formulator know in advance which grade of HPMCAS will work for a new API?
Publication 2: The thermodynamic answer
The second publication explains how this process works. Using amofor’s SOLCALC platform powered by PC-SAFT, we generated ternary NIF/polymer/water phase diagrams and compared the predicted phase behavior of NIF with PVPVA64 and HPMCAS.
The central conclusion is conceptually important: we must understand how precipitation inhibition in ASDs works within the thermodynamic framework of the API/polymer/water system.
Whether a polymer suppresses precipitation depends on the whole ternary system. It’s not a simple polymer trait. – Christian Lübbert, PhD
For ASDs containing fully water-soluble carrier polymers such as PVPVA64, the polymer dissolves completely during hydration. It cannot provide a consistent phase that can stabilize supersaturated API molecules. Without a polymer-rich phase to host the supersaturated drug, drug molecules concentrate in the aqueous phase until crystallization becomes the thermodynamically favored outcome; the “spring-and-collapse” behavior that frustrates many high drug-load ASD programs. It is important to note that adding more PVPVA64 to the dissolution medium does not solve the problem. The polymer dissolves into the bulk and never forms a polymer-rich colloidal phase. So, the problem is not concentration but the absence of a phase where the API is protected from its own desire to precipitate.
For HPMCAS, the situation is very different. Our model shows that HPMCAS forms a polymer-rich colloidal phase in water that can hold dissolved NIF. This colloidal phase acts as a thermodynamic reservoir for supersaturated API. It accommodates dissolved drug without driving it to crystallize, stopping or delaying precipitation. The mechanism is based on the polymer’s ability to form that phase, not on being part of the ASD itself. HPMCAS stabilizes supersaturation both as an ASD carrier and when added externally to the dissolution medium. That dual mode is an experimental fingerprint of a true thermodynamic system.
The difference between PVPVA64 and HPMCAS therefore lies in their phase behavior. When there is no polymer-rich phase to host the API, the system springs and collapses. The “spring-and-stay” phenomenon occurs when it does.
From mechanism to HPMCAS grade selection
Treating precipitation inhibition as a phase phenomenon is practically useful for HPMCAS grade selection. The HPMCAS L, M, and H grades differ in acetyl and succinoyl substitution, dispersibility, and hydrophobicity. Thus, each grade forms a different colloidal phase with a different capacity to host a given API.
The effect of preventing precipitation changes a lot from one grade to another, as does the release rate. Until now, the method of matching grades to APIs has been empirical.
With PC-SAFT modeling in SOLCALC, we can now systematically rank HPMCAS grades for any candidate API. The result is a guided recommendation: this grade, at this drug load, will form a colloidal phase capable of accommodating this API, and will (or will not) suppress precipitation.
For drug formulation scientists, the decision to use HPMCAS-grade materials is now defendable on thermodynamic grounds. Surprises at the dissolution step become predictable and explainable. Polymer screening cycles become more efficient, requiring fewer wet experiments to determine the correct grade and confirming more of our model-led hypotheses.
The impact extends beyond the laboratory. ASD precipitation risk, which was historically discovered late during biorelevant dissolution testing or even in vivo. It can now be assessed much earlier, at the candidate selection stage, when changes are inexpensive. Making polymer-grade decisions earlier with documented mechanistic justification also strengthens the regulatory justification. Discovering too late that the wrong HPMCAS grade was chosen is one of the largest unmanaged risks in ASD development. This risk is now manageable.
Work with us on your API
If you have a compound that doesn’t dissolve well and you’re trying to choose between PVPVA64 and HPMCAS, or between HPMCAS-L, -M, and -H, we can help.
HPMCAS is a unique polymer because it can form the phase that stabilizes supersaturation. With SOLCALC, powered by PC-SAFT, we can predict when that phase will form for your API, and rank HPMCAS-L, -M, and -H before you run a single wet experiment.
Contact Christian Lübbert for a consultation on your API.